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Abstract
Background: Symptom- and sexual history-based testing i.e., testing on indication, for anorectal sexually transmitted
infections (STIs) in women is common. Yet, it is unknown whether this strategy is effective. Moreover, little is known
about alternative transmission routes i.e. by fingers/toys. This study assesses anorectal STI prevalence and infections
missed by current testing practice, thereby informing the optimal control strategy for anorectal STIs in women.
Methods: Women (n = 663) attending our STI-clinic between May 2012-July 2013 were offered routine testing for
anorectal and urogenital Chlamydia trachomatis and Neisseria gonorrhoeae. Data were collected on demographics,
sexual behaviour and symptoms. Women were assigned to one of the categories: indication (reported anal
sex/symptoms), fingers/toys (only reported use of fingers/toys), or without indication.
Results: Of women, 92% (n = 654) participated. There were 203 reports (31.0%) of anal sex and/or symptoms
(indication), 48 reports (7.3%) of only using fingers/toys (fingers/toys), and 403 reports (61.6%) of no anal
symptoms, no anal sex and no anal use of fingers/toys (without indication). The overall prevalence was 11.2%
(73/654) for urogenital chlamydia and 8.4% (55/654) for anorectal chlamydia. Gonorrhoea infections were not
observed. Prevalence of anorectal chlamydia was 7.9% (16/203) for women with indication and 8.6% (39/451)
for all other women (P = 0.74). Two-thirds (39/55) of anorectal infections were diagnosed in women without
indication. Isolated anorectal chlamydia was rare (n = 3): of all women with an anorectal infection, 94.5%
(52/55) also had co-occurrence of urogenital chlamydia. Of all women with urogenital chlamydia, 71.2%
(52/73) also had anorectal chlamydia.
Conclusions: Current selective testing on indication of symptoms and sexual history is not an appropriate
control strategy for anorectal chlamydia in women visiting an STI clinic. Routine universal anorectal testing is
feasible and may be a possible control strategy in women. Yet costs may be a problem. When more
restricted control measures are preferred, possible alternatives include (1) anorectal testing only in women
with urogenital chlamydia (problem: treatment delay or loss to follow up), and (2) direct treatment for
urogenital chlamydia that is effective for anorectal chlamydia as well.
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Background
Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae
(Ng) are the most prevalent bacterial sexually transmit-
ted infections (STIs) in women in high income coun-
tries and have major public health consequences [1-3].
In addition to infection of the urogenital tract, chlamydia
and gonorrhoea can also cause anorectal infections in
women. Previous studies of women who visited an STI
clinic or a department of genitourinary medicine found
anorectal chlamydia in up to 18% [2,4-11] of them and
gonorrhoea in up to 13% of them [4-10]. However, guide-
lines in UK, US and the Netherlands do not recommend
routine anorectal testing, but restricted testing in people
who are in high-risk groups, report anal sexual behaviour,
or have anal symptoms [12], i.e., selective testing on indi-
cation [12,13]. This is in contrast to urogenital testing,
which is a routine procedure in STI care services in these
countries. Nucleic acid amplification tests (NAATs) are
the most sensitive tests for the screening and diagnosis of
genital chlamydial infections to date, and their use is ac-
cepted and recommended for anorectal infections as well
[14]. The impact of anorectal infections in women on
population (public health) and individual (clinical) level
are yet unknown. However, it is suggested that treatment
of anorectal infections in women can help limit the spread
of STI in the population [4-6] and can reduce complica-
tions in infected individuals, such as anal cancer, anal
squamous intraepithelial lesions [15,16] and reduce HIV
risk [5,6]. Moreover, the rectum might act as a reservoir
and thereby play a major role in repeat positive urogenital
infections [4].
In the control of anorectal chlamydia there are 2 key
stones: first is identification (diagnosis by testing) and
second is treatment. In high risk groups there is evi-
dence that many anorectal STI are missed by current
testing practice on indication. A study using routine uni-
versal anorectal testing in high-risk women found that
selective testing on indication misses over half of ano-
rectal infections (48% Ct, 80% Ng) [17]. It is unknown
whether selective testing on indication misses infections
in the general female population, due to lack of studies in
this population.
Adequate treatment for anorectal chlamydia is cur-
rently under debate. Guidelines in the UK and US rec-
ommend both single-dose azithromycin and a 7-day
course of doxycycline as equal treatments for uncompli-
cated anorectal chlamydia in non pregnant women [12].
In the Netherlands, doxycycline is recommended for
anorectal chlamydia [13]. Several studies have reported
substantial microbial failure rates of up to 40% for
single-dose azithromycin (1.0 g) used against anorectal
chlamydia [18-22], or suggest that doxycycline may be
more effective than azithromycin in the treatment of rec-
tal chlamydial infections [23]. Anorectal control strategies
(treatment and testing) are thereby in need of critical
reflection.
To inform optimal control strategies for anorectal
STIs in women, first the prevalence of anorectal STI was
determined by using routine universal collected data in
the general STI clinic population of women. Such data is
scarce, because of the general lack of a routine universal
screening practice in women in STI control settings.
Moreover, little is known about alternative transmission
routes such as the anal use of fingers and/or sex toys. By
assessing associations with medical and behavioural his-
tory, we aim to estimate the number of anorectal infec-
tions missed by the current practice of selective testing
on indication and to formulate recommendations for
control i.e., the testing and treatment strategies.
Methods
Study population
The outpatient STI clinic of the South Limburg Public
Health Service provides about 6000 consultations annu-
ally, offering free examination and treatment at three
regional outpatient STI clinics. Between May 2012 and
July 2013, three consultation nurses (out of 13) offered all
their female patients aged 18 years and older (n = 663)
routine testing for urogenital and anorectal chlamydia and
gonorrhoea. This yielded a total of 654 consultations by
611 women for analysis (participation 92.2%). Fifty-two
(7.8%) women declined an anorectal swab; reported rea-
sons for non-participation were inconvenience (65%), fear
(19%) and lack of necessity (16%). Non-participants were
slightly younger than participants (median 21 years versus
23 years, P < 0.001). Urogenital chlamydia prevalence
was similar for non-participants and participants (13.5%;
(7/52) versus 11.2% (73/654), P = 0.60). Gonorrhoea infec-
tions were not observed in both groups. The study was ap-
proved by the Medical Ethics Committee of Maastricht
University (11-4-108).
Study procedures and definitions
Women provided self-collected vaginal swabs and self-
collected anorectal swabs, which studies have proven to
be a generally acceptable, valid and feasible approach
[3,24,25]. Trained study nurses provided women with a
visual diagram and oral instructions about how to take
separate self-collected vaginal and rectal swabs. For the
vaginal swab, the patient was instructed to insert the
swab 2.5 cm into the vagina, rotate it for 5 to 10 seconds,
and then place it in a capped tube to avoid potential
contamination. This procedure was repeated in the anus
for the rectal swab. Samples were tested for Chlamydia
trachomatis and Neisseria gonorrhoeae using nucleic
acid amplification assays according to the manufac-
turer’s procedure (polymerase chain reaction [PCR; Roche
Cobas 4800, San Francisco, CA]). Serum was tested for
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Treponema pallidum hemagglutination (TPHA) and HIV;
all the women were TPHA and HIV negative. Each con-
sult also included a standardised medical and sexual
history taken by trained study nurses. It asked about
self-reported symptoms and sexual behaviour in the
past six months, i.e., ‘Did you practise anal sex in the
past six months?’. Anal symptoms included rectal dis-
charge, bleeding, pain, redness, burning sensation, or
itching. Swingers were defined as women who were part
of a male–female couple that had sex with other male–
female couples and their self-identified heterosexual sex
partners. Prostitutes were defined as women who re-
ported having had sex for money in the past six months.
Women who were prostitute and/or swinger were defined
as prostitutes/swingers. All data was registered in an elec-
tronic patient registry.
Statistical analysis
Women were assigned to one of three non-overlapping
hierarchically constructed indication categories based
on reported behaviour and symptoms. Women in the
“indication” category reported at least anal symptoms
and/or anal sex, whether or not in combination with anal
use of fingers and/or toys. Women who were assigned to
the “fingers/toys” category only reported the anal use of
fingers and/or toys and reported no anal symptoms and
no anal sex. Women who reported no anal symptoms, no
anal sex, and no anal use of fingers or toys were assigned
to the “without indication” category. As no gonorrhoea in-
fections were observed, statistical analyses focussed on
chlamydia only. The prevalence of chlamydia was calcu-
lated by dividing the number of positive tests by the total
number of tests, multiplied by 100. Univariate and multi-
variate logistic regression were used to identify determi-
nants independently associated with anorectal chlamydia.
Determinants tested were indication (with indication
versus the two other categories combined), age categor-
ies, prostitutes/swingers (prostitutes and swingers versus
other women), and use of fingers/toys (versus no use of
fingers/toys). Anorectal infections in the categories “with-
out indication” and “fingers/toys” were defined as in-
fections missed by selective testing on indication as
in current care. The share of infections missed was
compared between indication categories, age categories
(reference ≥ 29 years) and prostitutes/swingers using uni-
variate and multivariate logistic regression. Interac-
tions terms were added between indication categories,
age categories and prostitutes/swingers in the multi-
variate models, but none were statistically significant
and were removed from in the final models.
Finally, to assess the anatomic site distributions of uro-
genital and anorectal chlamydia, all women who tested
positive for chlamydia were assigned to a non-overlapping
distribution category: (1) urogenital only, (2) urogenital
and anorectal, or (3) anorectal only. Restricting to chla-
mydia positives, this variable was compared over indi-
cation categories (with indication versus the two other
categories combined), age categories, and prostitutes/
swingers using Fisher’s exact test. A P value of < 0.05
was considered statistically significant. Analyses were
performed using SPSS version 17.0.0 (IBM Inc., Somers,
NY, USA). Written informed consent for participation
in the study was obtained from participants. Written
informed consent was not obtained from a parent or
guardian.
Results
We included 654 consultations with an overall median
participant age of 23 years (inter-quartile range: 21 to 34).
The overall prevalence was 11.2% (73/654) for urogenital
chlamydia and 8.4% (55/654) for anorectal chlamydia.
Gonorrhoea infections were not observed. Overall, anal
use of fingers was reported by 20.3% (133/654) of the
women, anal use of toys by 8.9% (58/654), anal sex with a
steady partner by 24.0% (157/654), anal sex with a casual
partner by 13.1% (86/654) and anal symptoms by 3.1%
(20/654). Anal symptoms reported were itching (n = 7), ul-
ceration (n = 3), redness (n = 2), discharge (n = 1), pain/
burning sensation (n = 5), bleeding (n = 3) and unspecified
(n = 2). Only 3 women reported a combination of (two)
symptoms.
Indication categories
In total, 31.0% (203/654) of the women were assigned to
the “indication” category (i.e., they reported anal sex and/
or symptoms), 7.3% (48/654) to the “fingers/toys” category
(reported anal use of fingers/toys only), and 61.6%
(403/654) to the “without indication” category (no re-
ported anal symptoms, no anal sex, and no anal use of
fingers/toys). Women without indication were younger
than women with indication (median of 22 years versus
36 years). The share of prostitutes/swingers was higher in
women using fingers/toys only compared to women with-
out indication (Table 1).
Chlamydia prevalence and associated determinants
Prevalence of anorectal chlamydia was 7.9% (16/203) for
women with indication and 8.6% (39/451) for the other
women (categories without indication and fingers/toys)
(P = 0.74). Prevalence in the three indication categories
is displayed in Table 1. Young age was the only deter-
minant associated with anorectal chlamydia (≤ 21 years
14.2% (odds ratio 3.79 (1.75-8.20)), 22–28 years 7.0%
(odds ratio 1.73 (0.75-4.00) and ≥ 29 years 4.2%). Being
prostitute/swinger was not associated with anorectal
chlamydia; prevalence was 3.0% (5/168) for prostitutes/
swingers versus 10.3% (50/486) for other women (P = 0.13).
In total, 136 women reported to have used fingers or toys,
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whether or not in combination with anal sex. Prevalence
in those women was 5.1% (7/136) versus 9.3% (48/518)
in women who did not report to have used fingers or
toys (P = 0.82).
Missed infections by selective testing on indication
In total, 55 anorectal chlamydia infections were diag-
nosed; 67.3% (37/55) were diagnosed in women without
indication (Table 1). Only 2/55 anorectal infections were
diagnosed in the fingers/toys category. Combining fingers/
toys with the without indication category (as is usually the
case in current care), the proportion missed by current
care that uses selective testing was 70.9% (39/55). No
determinants were found to be associated with missed
anorectal infections. For example the proportion missed
was 60.0% in prostitutes/swingers versus 72.0% in other
women (P = 0.93). The proportion missed was 70.0% in
age ≤ 21 years, 81.3% in age 22–28 years and 55.6% in
age ≥ 29 years (P = 0.47).
Anatomic site distribution
Of all urogenital and anorectal chlamydia infections found,
68.4% (52/76) were concurrent urogenital and anorectal
infections. Of all chlamydia infections, only three infec-
tions were isolated anorectal (3.9%, 3/76): two in women
with indication and one in a woman without indication
(Figure 1). Of the 73 women with urogenital chlamydia,
71.2% (52/73) also had an anorectal chlamydia infection.
Of the 55 women with anorectal chlamydia, 94.5% (52/55)
also had a urogenital chlamydia infection. The anatomic
site distribution of chlamydia infections was not associated
with indication categories (P = 0.31), age (P = 0.90), or
prostitutes/swingers (P = 0.27) (Table 1).
Discussion
This study revealed alarmingly high numbers of anorec-
tal chlamydia in women. One in 12 women and even
one in 7 young women was diagnosed with anorectal
chlamydia. As over two thirds of these infections are
currently being missed, current selective testing on indi-
cation of symptoms and anal sexual history is not an ap-
propriate control strategy for anorectal chlamydia in
women visiting an STI clinic. Almost all women with
anorectal chlamydia had concurrent urogenital chla-
mydia (95%). To our knowledge, this is the first study
with routine universal anorectal testing, i.e., independent
Table 1 Characteristics of women attending the STI clinic routinely screened for urogenital and anorectal chlamydia
Indication# Fingers/toys only Without indication Total
N = 203 N = 48 N = 403 N = 654
% (n) % (n) % (n) % (n)
Age
≤ 21 years 19.2 (39)** 12.5 (6)** 41.2 (166) 32.3 (211)
22-28 years 27.1 (55) 25.0 (12) 40.0 (161) 34.9 (228)
≥ 29 years 53.7 (109) 62.5 (30) 18.9 (76) 32.9 (215)
Prostitutes/swingers 39.4 (80)* 66.7 (32)* 13.9 (56) 25.7 (168)
Chlamydia prevalence
Urogenital 9.4 (19) 4.2 (2) 12.9 (52) 11.2 (73)
Anorectal 7.9 (16) 4.2 (2) 9.2 (37) 8.4 (55)
Anatomic site distribution chlamydia positives N = 21 N = 2 N = 53 N = 76
Urogenital only 23.8 (5) 0 (0) 30.2 (16) 27.6 (21)
Anorectal only 9.5 (2) 0 (0) 1.9 (1) 3.9 (3)
Urogenital and anorectal 66.7 (14) 100 (2) 67.9 (36) 68.4 (52)
*P < 0.0001 compared to without indication by Chi square test.
**P < 0.0001 compared to without indication and age 29 years or older by Chi square test.
#Women with indication reported anal use of fingers and/or toys in 43.3% of consultations, symptoms in 9.9%, anal sex with a steady partner in 77.3%, and anal
sex with a casual partner in 42.4%.
Urogenital only (27,6%, n=21)
Urogenital and anorectal
(68,4%, n=52)
Anorectal only (3,9%, n=3)
Figure 1 Anatomic site distribution of chlamydia in women
attending the STI clinic routinely screened for urogenital and
anorectal chlamydia.
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of reported behaviour, symptoms or urogenital positivity,
in a general group of women who visited an STI clinic
and who took different sexual risks, including anal use
of fingers and toys.
Indication (anal sex or symptoms) was not associated
with anorectal chlamydia. Yet current guidelines for ano-
rectal STIs advocate selective symptom- and sexual his-
tory based testing for women [12,13]. Including the anal
use of fingers/toys in this testing on indication would
only reveal a small number of missed infections (3.6%),
as these practices are common but rarely practiced with-
out anal sex (7%). Moreover, use of fingers/toys was not
associated with anorectal chlamydia. This suggests that
anal use of fingers/toys, as well as report of anal sex or
symptoms are not useful indicators to guide testing for
anorectal chlamydia.
The prevalence of anorectal chlamydia was substantial
(8%) (55/654). Young age (≤ 21 years) was found to be
associated with anorectal chlamydia showing a strikingly
high 14% prevalence in this group of women, consistent
with studies in high risk women visiting an STI clinic
[5,6,9]. Thereby the absolute number of anorectal infec-
tions that are currently missed in the general female
STI clinic population is likely substantial, especially in
young women. This is consistent with earlier findings
in high-risk groups at our clinic, such as female swingers
(chlamydia 48%, gonorrhoea 80%) and men who have
sex with men (MSM) (chlamydia 43-55%, gonorrhoea
29-100%) [17]. More data is needed from other settings to
confirm our observations by routine anorectal testing.
In contrast to MSM, anorectal chlamydia in women
was rarely isolated. In current study, one woman had an
isolated anorectal infection but did not report anal sex
or symptoms. Possible explanations for this could be
underreporting, a false negative urogenital test [4,8], or
autoinoculation from a spontaneously cleared urethral/
vaginal infection [4,5]. The large percentage of concur-
rent urogenital and anorectal chlamydia infections in
women was therefore notable: 95% of women with ano-
rectal chlamydia also had urogenital chlamydia, and 71%
of women with urogenital chlamydia also had anorectal
chlamydia. Previous studies without routine universal
testing in women also reported large shares of concur-
rent infections (36-90%) [2,4-10,26]. It is not clear what
causes these concurrent infections, although possible ex-
planations could be underreporting of anal sex, autoinocu-
lation with vaginal secretions [4,5,8,9,26] or concurrent
transmission during sex. Majority (71%) of anorectal chla-
mydia positives did not report anal sex or symptoms.
Autoinoculation from the vagina to the rectum there-
fore seems possible. We hypothesize that autoinocula-
tion could also occur from the rectum to the vagina.
Even in the absence of sexual activity, the gastro intestinal
tract could provide a constant source of organisms which
may reinfect the genital tract [27]. Such (repeat) urogenital
infections could lead to reproductive tract morbidity [6].
Further study on this subject is needed, for example by
including anorectal chlamydia in mathematical models
and by bacterial load studies, the clinical and public
health impact of anorectal chlamydia in women could
be explored further.
Nevertheless, state of the art practice in chlamydia
control entails the use of highly sensitive NAATs to test
for chlamydia. Although NAATs are not yet FDA proved
for anorectal testing, their use is highly recommended,
accepted, and part of standard operating procedures in
many care settings [14]. A positive NAAT, i.e., diagnosed
anorectal chlamydia, is in practice followed by antibiotic
treatment. In MSM, an anorectal swab positive for chla-
mydia is considered an infection, and is treated with an-
tibiotics to prevent transmission to the population and
complications in individuals. To overcome current insuf-
ficient case management of anorectal infections in
women, testing and treatment strategies need to be im-
proved, to better identify and treat infections. Study par-
ticipation was high (93%), suggesting a high feasibility
and acceptability of anorectal testing in women who do
not have an indication. Therefore, routine universal ano-
rectal screening could be an option, although this will
increase costs substantially. No studies have evaluated
cost effectiveness of anorectal screening for chlamydia/
gonorrhoea in women. However, in MSM, anorectal
screening (when prevalence > 2.69% (IQR, 1.68-3.71%))
can be a cost-effective intervention to reduce HIV infec-
tion [28-30].
When a more restricted policy is preferred, anorectal test-
ing only in women with urogenital infection or direct treat-
ment effective for both urogenital and non-urogenital
chlamydia would detect and treat 95% of anorectal infec-
tions, since 52 of 55 anorectal infections had co-occurrence
of urogenital chlamydia. However, for the former option
delay between urogenital and anorectal tests and subse-
quent treatments could be a problem in practice. The
substantial anorectal chlamydia prevalence and high
co-occurrence with urogenital chlamydia fuels the need
for debate on what is adequate treatment for anorectal
chlamydia [18-21,23]. The currently used treatment re-
gimes for uncomplicated anorectal chlamydia both have
drawbacks; higher treatment failure rates are reported for
azithromycin [19-21,23] and compliance for doxycycline
could possibly be an issue in practice [31]. More research,
for example a randomised controlled trial of azithromycin
versus doxycycline, including compliance, is needed to
formulate treatment recommendations.
Several study limitations need to be acknowledged.
We only included women who visited the STI clinic, so
our results might not fully represent those that could be
found in the general female population or within other
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healthcare settings. Although our instructions on speci-
men collection were clear, we cannot entirely rule out
the possibility of specimen contamination (e.g., via the
urogenital-anorectal route). As women attending the
STI clinic were randomly assigned to a consultation nurse,
possible selection bias is likely minimal. Data on other
high risk sexual behaviors (i.e., number of partners, new
or concurrent partnerships, substance use, condom use)
were not available, and their association with anorectal
chlamydia in women could not be assessed. In our study,
the prevalence or the proportion of infections missed
by current selective testing in the non-participants is
unknown. Eligible non-participants were slightly younger
than participants. A study by Sethupathi et al. found
women most at risk for anorectal infections included
women aged < 20 years as was also found in current study.
Therefore, the prevalence of anorectal infections may be
underestimated in current study, yet due to the high re-
sponse (93%), bias is expected to be minimal.
Conclusions
In conclusion, prevalence of anorectal chlamydia in women
was high and current selective testing on indication is not
an appropriate control strategy to identify and treat ano-
rectal chlamydia infections. Almost all women with ano-
rectal chlamydia had concurrent urogenital chlamydia.
More research is needed on the public health and clinical
implications of anorectal chlamydia in women.
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